TP53 and acute myeloid leukemia: We divided the ELN 2022 adverse-risk group into the following two subcategories based on the TP53 mutation status: AML TP53 mutant group (adverse TP53 Mut) and AML adverse TP53 wild-type group (adverse TP53 WT).